Defence Therapeutics Net Income
| DTCFF Stock | USD 0.44 0.01 2.33% |
As of the 9th of February, Defence Therapeutics shows the Standard Deviation of 5.33, mean deviation of 3.96, and Variance of 28.4. Defence Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Defence Therapeutics, which can be compared to its peers. Please confirm Defence Therapeutics variance, as well as the relationship between the maximum drawdown and skewness to decide if Defence Therapeutics is priced favorably, providing market reflects its regular price of 0.44 per share. As Defence Therapeutics is a penny stock we also recommend to verify its jensen alpha numbers.
Defence Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Defence Therapeutics' valuation are provided below:Defence Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Defence |
Defence Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Defence Therapeutics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Defence Therapeutics.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Defence Therapeutics on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Defence Therapeutics or generate 0.0% return on investment in Defence Therapeutics over 90 days. Defence Therapeutics is related to or competes with Sernova Corp, Cynata Therapeutics, Microbix Biosystems, Starpharma Holdings, Celyad Oncology, and Finch Therapeutics. Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar ther... More
Defence Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Defence Therapeutics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Defence Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 28.04 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 10.2 |
Defence Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Defence Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Defence Therapeutics' standard deviation. In reality, there are many statistical measures that can use Defence Therapeutics historical prices to predict the future Defence Therapeutics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.44) |
Defence Therapeutics February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 3.96 | |||
| Coefficient Of Variation | (2,113) | |||
| Standard Deviation | 5.33 | |||
| Variance | 28.4 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 28.04 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 10.2 | |||
| Skewness | 0.3306 | |||
| Kurtosis | 0.6846 |
Defence Therapeutics Backtested Returns
Defence Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0674, which denotes the company had a -0.0674 % return per unit of risk over the last 3 months. Defence Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Defence Therapeutics' Variance of 28.4, standard deviation of 5.33, and Mean Deviation of 3.96 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.59, which means possible diversification benefits within a given portfolio. As returns on the market increase, Defence Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Defence Therapeutics is expected to be smaller as well. At this point, Defence Therapeutics has a negative expected return of -0.35%. Please make sure to confirm Defence Therapeutics' information ratio, skewness, day typical price, as well as the relationship between the treynor ratio and daily balance of power , to decide if Defence Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.22 |
Weak predictability
Defence Therapeutics has weak predictability. Overlapping area represents the amount of predictability between Defence Therapeutics time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Defence Therapeutics price movement. The serial correlation of 0.22 indicates that over 22.0% of current Defence Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.22 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Defence Therapeutics reported net income of (7.34 Million). This is 102.15% lower than that of the Healthcare sector and 110.48% lower than that of the Biotechnology industry. The net income for all United States stocks is 101.29% higher than that of the company.
Defence Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Defence Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Defence Therapeutics could also be used in its relative valuation, which is a method of valuing Defence Therapeutics by comparing valuation metrics of similar companies.Defence Therapeutics is currently under evaluation in net income category among its peers.
Defence Fundamentals
| Return On Equity | -4.15 | |||
| Return On Asset | -1.79 | |||
| Current Valuation | 60.32 M | |||
| Shares Outstanding | 37.85 M | |||
| Shares Owned By Insiders | 5.26 % | |||
| Price To Book | 36.71 X | |||
| EBITDA | (7.32 M) | |||
| Net Income | (7.34 M) | |||
| Cash And Equivalents | 506.7 K | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 0.61 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (6.04 M) | |||
| Earnings Per Share | (0.15) X | |||
| Market Capitalization | 143.45 M | |||
| Total Asset | 719.67 K | |||
| Z Score | -33.0 | |||
| Net Asset | 719.67 K |
About Defence Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Defence Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Defence Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Defence Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Defence OTC Stock
Defence Therapeutics financial ratios help investors to determine whether Defence OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Defence with respect to the benefits of owning Defence Therapeutics security.